Forsta AP Fonden Has $15.01 Million Stock Position in STERIS plc $STE

Forsta AP Fonden boosted its position in STERIS plc (NYSE:STE) by 34.7% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 62,500 shares of the medical equipment provider’s stock after acquiring an additional 16,100 shares during the quarter. Forsta AP Fonden’s holdings in STERIS were worth $15,014,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of STE. Spurstone Advisory Services LLC acquired a new stake in shares of STERIS in the second quarter valued at about $29,000. Geneos Wealth Management Inc. lifted its position in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Zions Bancorporation National Association UT bought a new stake in STERIS during the 1st quarter valued at approximately $37,000. Costello Asset Management INC acquired a new stake in STERIS in the 1st quarter valued at approximately $45,000. Finally, Atticus Wealth Management LLC bought a new position in STERIS in the 2nd quarter worth approximately $68,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on STE. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Morgan Stanley increased their price target on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, August 8th. KeyCorp raised their price target on shares of STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $273.50.

STERIS Stock Up 0.4%

STE opened at $267.82 on Thursday. The company has a market capitalization of $26.38 billion, a P/E ratio of 41.01 and a beta of 1.02. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. The firm’s fifty day moving average price is $245.36 and its two-hundred day moving average price is $239.86. STERIS plc has a fifty-two week low of $200.98 and a fifty-two week high of $268.30.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.09. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the prior year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, analysts anticipate that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be paid a dividend of $0.63 per share. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a yield of 0.9%. STERIS’s dividend payout ratio (DPR) is currently 36.21%.

Insider Buying and Selling

In other STERIS news, CEO Daniel A. Carestio sold 159 shares of the company’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the sale, the chief executive officer directly owned 51,096 shares in the company, valued at $12,356,034.72. This represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Renato Tamaro sold 3,204 shares of STERIS stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $249.24, for a total value of $798,564.96. Following the transaction, the vice president directly owned 7,221 shares of the company’s stock, valued at approximately $1,799,762.04. The trade was a 30.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.07% of the stock is currently owned by insiders.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.